A Unique Case of Heat-Induced Livedo Reticularis Following Initiation of Upadacitinib
Main Article Content
Keywords
livedo reticularis, upadacitinib, janus kinase inhibitor, vascular rash, reticulated rash
Abstract
Livedo reticularis is a benign condition characterized by a mottled appearance of the skin that is most frequently triggered by exposure to cold temperatures. It is painless and often self-resolves after trigger avoidance. Upadacitinib is a Janus kinase inhibitor approved for the treatment of several inflammatory and autoimmune diseases including atopic dermatitis and psoriatic arthritis. Here, we report a case of heat-induced livedo reticularis following initiation of treatment with upadacitinib for an ixekizumab-triggered paradoxical eczematous flare. This presentation expands the spectrum of cutaneous vascular changes potentially associated with JAK-inhibitors and underscores the importance of clinician awareness to support counseling, avoid unnecessary workup, and guide ongoing monitoring.
References
2. Quaresma MV, Gomes AC, Serruya A, Vendramini DL, Braga L, Buçard AM. Amantadine-induced livedo reticularis--Case report. An Bras Dermatol. 2015;90(5):745-747. doi:10.1590/abd1806-4841.20153394
3. Horino T, Inotani S, Nakajima K, Terada Y. Livedo Reticularis After COVID-19 Vaccination. J Rheumatol. 2023;50(5):709. doi:10.3899/jrheum.220584
4. Miot HA, Criado PR, de Castro CCS, Ianhez M, Talhari C, Ramos PM. JAK-STAT pathway inhibitors in dermatology. An Bras Dermatol. 2023;98(5):656-677. doi:10.1016/j.abd.2023.03.001
5. Mytheen S, Varghese A, Joy J, Shaji A, Tom AA. Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS). Expert Opin Drug Saf. 2023;22(10):985-994. doi:10.1080/14740338.2023.2223955
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.